Key result
Activation of autocrine and paracrine signaling pathways by stromal cell-derived factors contributes to cardiovascular disease progression, making stromal cells a potential therapeutic target.
Targeting stromal cells via pharmacological agents or gene delivery may offer novel therapeutic strategies for preventing or attenuating cardiovascular disorders.
Stromal cell pathways may influence cardiovascular disease progression; leaves open mechanistic and clinical validation in prospective studies.
Stromal cells, composed of fibroblasts, microvascular endothelial cells, immune cells and inflammatory cells, are critical determinants of the mechanical properties and function of the heart and vasculature, and the mechanisms whereby these types of cells are activated are important to understand the progression of cardiovascular diseases. Emerging studies have suggested that the activation of autocrine and paracrine signaling pathways by stromal cell-derived growth factors, cytokines and bioactive molecules contributes to disease progression. Disruption of the stromal network will result in alterations in the geometry and function in these organs. Interventions targeting the stromal cells (eg, myofibroblasts, microvascular endothelial cells, inflammatory cells) by pharmacological agents or direct gene delivery/small interfering RNA would be potential novel therapeutic strategies to prevent/attenuate the progression of cardiovascular disorders.
No takes yet. Share an insight, caveat, or question.
Tsuruda et al. (2010) conducted a review in Cardiovascular diseases. Activation of autocrine and paracrine signaling pathways by stromal cell-derived factors contributes to cardiovascular disease progression, making stromal cells a potential therapeutic target.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Circulation Journal